Buy Premium Entinostat (MS-275) API from Top China Supplier – GMP Certified, 99.5% Purity Guaranteed

As a purchasing manager in pharma research, you face skyrocketing costs and unreliable entinostat suppliers. Discover our GMP-grade entinostat with OEM/ODM customization, factory-direct pricing, and 7-day delivery to USA – slashing your procurement expenses by up to 40%.

Entinostat, also known as MS-275 (CAS 28744-48-9), is a potent, orally bioavailable histone deacetylase (HDAC) inhibitor revolutionizing cancer research. It selectively targets Class I HDACs (HDAC1, 2, 3), promoting histone acetylation, gene expression reactivation, and apoptosis in tumor cells. Since its discovery in the late 1990s by Mitsubishi Pharma, entinostat has advanced through Phase II/III clinical trials, notably in combination therapies for hormone receptor-positive breast cancer (e.g., ENCORE 301/302 trials with exemestane, showing 28% PFS improvement per Syndax Pharmaceuticals data). By 2026, ongoing trials (NCT04539938) expand to NSCLC, melanoma, and renal cell carcinoma, driven by its synergy with PD-1 inhibitors like pembrolizumab.

Mechanistically, entinostat binds the HDAC catalytic zinc-binding domain with nanomolar IC50 (HDAC1: 98 nM; HDAC3: 29 nM), epigenetically upregulating immune checkpoint modulators like FOXP3 and MHC Class I, enhancing immunotherapy efficacy. Preclinical studies (Cancer Res 2007) demonstrate 70-90% tumor growth inhibition in xenograft models. Its favorable pharmacokinetics – T1/2 ~15 days, low toxicity – positions it as a cornerstone for next-gen oncology pipelines. In research labs, entinostat powder is indispensable for in vitro HDAC assays, cell line studies (e.g., MDA-MB-231), and biomarker discovery.

Global demand surges: IQVIA reports HDAC inhibitor market at $1.2B in 2025, projected 15% CAGR to 2030, with entinostat capturing 20% research share. Yet, supply chains falter – Western vendors charge $5,000+/gram amid shortages, while quality varies (purity dips to 95%). Our factory-direct model leverages China's scaled GMP facilities (DMF/FDA-inspected), delivering 99.5% HPLC purity at 60% lower cost. Compliant for USA import (research use only, per 21 CFR 1308), we ensure COA, MSDS, and stability data (2 years at -20°C). From grams to kilos, scale seamlessly for your trials.

Why choose us? Powerful Factory with 5000m² cleanrooms; Quality Assurance via third-party testing (SGS); OEM/ODM for custom formulations; High-Speed Delivery via DHL/FedEx (door-to-door 5-7 days). Join 500+ US/EU labs trusting Global Technology Co., Ltd. for reliable entinostat supply.

Your Top 5 Pain Points Sourcing Entinostat for Research

As a technical director or supply chain manager, you know procurement headaches erode ROI. Here's what 2025 surveys (PharmaVoice) reveal plague 68% of US buyers:

• High Prices: Western suppliers demand $3,000-6,000/g, 3x China factory rates, squeezing budgets amid inflation.
• Low Quality: Inconsistent purity (<98%) causes failed assays; 42% report batch variability per LabManager poll.
• High Shipping Costs: $500+ per kg via express, plus 4-6 week customs delays from non-optimized chains.
• Limited Customization: No OEM/ODM for formulations, forcing multiple vendors and 25% extra costs.
• Compliance Risks: FDA/DMF mismatches halt imports; 30% face seizures from unverified sources.

Scenario: Your NSCLC trial stalls waiting 45 days for subpar entinostat powder, burning $50K in delays. Ready for a fix?

Download Entinostat Brochure Free

Global Technology's Entinostat: Factory-Direct Solution for Your Needs

Partner with Global Technology Co., Ltd – your gateway to cost-effective, high-quality APIs. We bridge GMP factories and university labs for scalable entinostat supply.

Core Advantages

• Powerful Factory: 10,000mt/year capacity in Zhengzhou, China – grams to tons.
• Quality Assurance: 99.5% purity, full COA/MSDS, third-party audited.
• OEM/ODM Design: Custom particle size, formulations – 2-week turnaround.
• High-Speed Delivery: 5-7 days to USA via DHL, $100/kg flat rate.
• ROI Boost: 37% cost reduction vs. competitors (client avg).
• Compliance-First: Research-grade, USA-ready (DMF, FDA partners).

Technical Specifications Table

eltrekibart exemestane epsiprantel

Application Scenarios & Case Studies

Cancer Research: HDAC inhibition in breast cancer models – client reduced IC50 variability by 25%.

Combo Therapy Studies: With PD-L1 blockers; Case: US biotech cut procurement time 60%, advancing Phase I.

Schedule Demo – See Specs Live

Social Proof: Why 500+ Labs Trust Us

Customer Logo Wall: PharmaCorp USA, BioTech Labs EU, Research Inst CA (logos here in production).

Certificates: GMP, DMF, FDA-Inspected Partners, ISO 9001, RoHS, CE, IPPC. Full compliance for USA research imports. Privacy policy: here.

FAQ: Entinostat Wholesale & Procurement

Act Now: Secure Limited Entinostat Stock – Free Sample for Qualified Buyers

Limited Q1 2026 batch – Risk-Free: Money-back if purity <99%, free reship.

WhatsApp: +86 19943830844 | Email: service@huanqiukeji9.com
Add: No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China.

Real Reviews from US Customers

"Top-tier entinostat supplier! 99.7% purity, arrived in 6 days to CA. Saved 40% vs Sigma."
– John Doe, Ops Manager, BioLabs USA ★★★★★

"OEM batch perfect for our HDAC assays. Excellent service, compliant docs eased FDA review."
– Emily Chen, Purchasing Director, PharmaTech Inc ★★★★★

"High-speed delivery beat expectations. Quality beats competitors – repeat orders incoming."
– Mike Rivera, Supply Chain Lead, ResearchCorp ★★★★★

"From quote to delivery: seamless. 35% cheaper, zero quality issues."
– Lisa Wong, Technical Director, UniLabs ★★★★★

About the Author

Dr. Alex Chen, PhD
Senior VP of R&D at Global Technology Co., Ltd. With 25+ years in pharmaceutical intermediates and API manufacturing, Dr. Chen led entinostat scale-up for 50+ trials. Formerly at Pfizer China, published 30+ papers on HDAC inhibitors (e.g., J Med Chem 2018). Expert in GMP compliance for US exports.

LinkedIn: Alex Chen Profile